Moa Fransson

Moa Fransson

Company: Genagon Therapeutics

Job title: CEO


Targeting a Novel Target on Tumor Associated Macrophages In Triple Negative Breast Cancer – Opportunity For A First-In-Class Therapeutic 2:30 pm

Genagon has characterized a novel target within immuno-oncology specialized for cancers with a high infiltration of macrophages. The target accumulates on the surface of cells within the tumor, enabling treatment with low risk of side-effects Genagon is targeting novel biology with an opportunity for a first- in-class therapeutic in the $500 million market triple negative…Read more

day: Discovery & Pre-Clinical Development - Day 1 pm

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.